Antitope Limited, UK. Announces Antibody Research Agreement with Dana-Farber Cancer Institute, Inc.
23rd February 2007 - Antitope Ltd., announced a research agreement with the Dana Farber Cancer Institute, Inc. ("Dana-Farber") for the generation of novel biologics for the potential treatment of cancer and infectious disease. As part of the agreement, Antitope will apply its proprietary Composite Human AntibodyTM technology to multiple targets identified by Dana-Farber to produce therapeutic antibodies with a reduced risk of immunogenicity.
"We are honoured to be collaborating with Dr Freeman's laboratory to develop therapies from their pioneering discoveries in relation to PD ligands and T cell exhaustion. We believe that PD ligand related targets have great potential for the development of new and highly effective treatments for cancer and infectious diseases.". said Dr Matthew Baker, Chief Scientific Officer of Antitope Limited. "This partnership especially combines Antitope's expertise in antibody humanization with Dana Farber's expertise in T cell biology.to create a new class of biologics for potential use in a broad range of diseases."
About Antitope
Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary Composite Human Antibody technology builds upon the previous pioneering work of its founders in the detection and removal of T cell epitopes in antibodies/proteins through humanization and de-immunisation technologies. Antitope are a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit http://www.antitope.co.uk/.
About Dana Farber Cancer Institute
Dana-Farber Cancer Institute (http://www.dana-farber.org/) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.
For further information contact:
Dr Neil Butt
Business Development Director
Tel: +44 (0)1223 496190
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it